Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.The Motley Fool • Saturday
Bristol Myers Squibb Announces Evolution of Research & Development OrganizationBusiness Wire • Thursday
Our Bristol Myers Squibb Stock Pick Is Up 35%. It's Still a Good Bet in Healthcare.Barrons • Thursday
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up HeatBenzinga • Wednesday
Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income InvestorsThe Motley Fool • 11/07/26
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?The Motley Fool • 11/07/26
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific SessionsBusiness Wire • 11/06/26
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 11/04/26
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?The Motley Fool • 11/02/26
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 11/02/26
Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)Seeking Alpha • 10/30/26
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline ProgressZacks Investment Research • 10/30/26
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarZacks Investment Research • 10/30/26
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 EarningsZacks Investment Research • 10/29/26